Ten Programs To Watch Out For At ASCO

The ASCO abstracts are out – and with them a scramble to see exactly what will be hitting the headlines in early June. Here, with the help of Sagient's BioMedTracker, Scrip takes a look at some of the more interesting studies due to be presented in Chicago in a couple weeks.

test tube

Johnson & Johnson has the distinction of a late-breaking presentation on June 5 for the first quantitative data from its CASTOR study of Darzalex (daratumumab) in patients with relapsed/refractory multiple myeloma.

Darzalex received accelerated approval in November 2015 well ahead of schedule as a fourth-line treatment for multiple myeloma, but positive...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category